Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma

Clinical Cancer Research

Volumn 14, Issue 16, 2008, Pages 5099-5107

  Lazzarini, Raffaella ^a,b   Moretti, Simona ^a,b   Orecchia, Sara ^c   Betta, Pier Giacomo ^c   Procopio, Antonio ^a,b   Catalano, Alfonso ^a,b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

^c C Arrigo Children's Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; SHORT HAIRPIN RNA; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DRUG DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CHEMOSENSITIVITY; CLONOGENIC ASSAY; HUMAN; HUMAN CELL; IC 50; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; ANIMAL; APOPTOSIS; CELL AGING; CELL CYCLE; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENETIC TRANSFECTION; IMMUNOBLOTTING; MALE; MESOTHELIOMA; METABOLISM; MOUSE; NICK END LABELING; NUDE MOUSE; PHYSIOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CELL AGING; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HUMANS; IMMUNOBLOTTING; IN SITU NICK-END LABELING; MALE; MESOTHELIOMA; MICE; MICE, NUDE; RNA INTERFERENCE; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 52649163860     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0255     Document Type: Article

References (29)

1. Zucali PA, Giaccone G. Biology and management of malignant pleural mesothelioma. Eur J Cancer 2006; 42:2706-14.
2. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;73:539-42.
3. Catalano A, Rodilossi S, Rippo MR, Caprari P, Procopio A. Induction of stem cell factor/c-Kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells. J Biol Chem 2004:279:46706-14.
4. Schmitt CA, Fridman JS,Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002;109:335-46.
5. Schmitt CA. Senescence, apoptosis and therapy cutting the lifelines of cancer. Nat Rev Cancer 2003;3:286-95.
6. Campisi J, d′Adda di Fagagna F. Cellular senescence:when bad things happen to good cells. Nat Rev Mol Cell Biol 2007;8:729-40.
7. Yaswen P, Campisi J. Oncogene-induced senescence pathways weave an intricate tapestry. Cell 2007;128:233-4.
8. 1 arrest in human cancer cells. Cancer Res 1995:55:5187-90.
9. Isik R, Metintas M. Gibbs AR, et al. p53, p21 and met-allothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure. Respir Med 2001;95:588-93.
10. Metcalf RA, Welsh JA, Bennett WP, et al. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res1992;52:2610-5.
11. Mor O, Yaron P, Huszar M, et al. Absence of p53 mutations in malignant mesotheliomas. Am J Respir Cell Mol Biol 1997;16:9-13.
12. Kratzke RA, Otterson GA, Lincoln CE, et al. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 1995;87:1870-5.
13. Xio S, Li D, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 1995;11:511-5.
14. Nguyen DM, Schrump WD, Chen GA, et al. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res 2004;10:1813-25.
15. Catalano A, Caprari P, Moretti S, Faronato M, Tamagnone L, Procopio A. Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function. Blood 2006;107:3321-9.
16. Giuliano M, Catalano A, Strizzi L.Vianale G, Capogrossi M, Procopio A. Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells. Int J Mol Med 2000;5:591-6.
17. Catalano A, Rodilossi S, Caprari P, Coppola V, Procopio A. 5-Lipoxygenase regulates senescence like growth arrest by promoting ROS-dependent p53 activation. EMBO J 2005;24:170-9.
18. Rippo MR, Moretti S.Vescovi S, et al. FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene 2004;23:7753-60.
19. Collado M, GilJ, Efeyan A, et al. Tumour biology:senescence in premalignant tumours. Nature 2005;436:642.
20. Catalano A, Graciotti L, Rinaldi L, et al. Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. Int J Cancer 2004;109:322-8.
21. GraeberTG, Osmanian C, JacksT, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996;379:88-91.
22. Catalano A, Gianni W, Procopio A. Experimental therapy of malignant mesothelioma: new perspectives from anti-angiogenic treatments. Crit Rev Oncol Hematol 2004;50:101-9.
23. Weiss RH. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003;4:425-9.
24. Han Z.Wei W, Dunaway S, et al. Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J Biol Chem 2002;277:17154-60.
25. Hammill AK, Uhr JW, Scheuermann RH. Annexin V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death. Exp Cell Res 1999;251:16-21.
26. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1:639-49.
27. Chuang LS, Ian HI, KohTW, Ng HH, Xu G, Li BF. Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science 1997;277:1996-2000.
28. Flores-Rozas H, Kelman Z, Dean FB, et al. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase δ holoenzyme. Proc Natl Acad Sci U S A 1994;91:8655-9.
29. Suzuki A.Tsutomi Y, Miura M, Akahane K. Caspase 3 inactivation to suppress Fas-mediated apoptosis:identification of binding domain with p21 and ILP and inactivation machinery by p21. Oncogene 1999:18:1239-44.